About Merus

MISSION
Merus discovers and develops differentiating therapeutics aimed at substantially prolonging the lives of cancer patients. It is our strategy to use the power of bispecific antibody engineering and advanced screening technologies to develop biopharmaceuticals that engage the power of the immune system to kill tumor cells.
MANAGEMENT

Merus’ management team has a wealth of experience in biopharmaceutical drug discovery and development.

Ton Logtenberg, Ph.D (CEO, Executive Director)

Ton Logtenberg holds a Ph.D. in Medical Biology and is the founder of Merus B.V.

Hui Liu (Executive Vice President, CBO)

Hui Liu holds a Ph.D. in molecular biology and an MBA in finance.

Mark Throsby, Ph.D (Executive Vice President, CSO)

Mark Throsby has served as our Chief Scientific Officer since January 2013 and previously served as our Chief Operating Officer from October 2008 to January 2013. His responsibilities include strategic scientific leadership, management of discovery, pre-clinical research and translational research, business development support, external collaborations and partnerships management. Before joining Merus, from October 2000 to […]

Lex Bakker, Ph.D (Senior Vice President, CDO)

Lex Bakker holds a Ph.D. in Tumor Immunology from the University of Nijmegen and was a postdoctoral fellow at the DNAX Research Institute (Palo Alto, CA).

John de Kruif, Ph.D (Senior Vice President, CTO)

John de Kruif holds a Ph.D. in Biology and spent his scientific career on phage display and engineering of human antibodies.

L. Andres Sirulnik, M.D., Ph.D (Executive Vice President, CMO)

L. Andres Sirulnik has served as our Chief Medical Officer since October 2016.  Prior to joining Merus, Dr. Sirulnik was at Novartis Pharmaceuticals from 2008-2016, most recently serving as Vice President – Senior Global Clinical Program Head and Research Physician in Oncology Clinical Development.  From 2003-2008, Dr. Sirulnik was an attending physician in the leukemia […]

John J. Crowley (Executive Vice President, CFO)

John J. Crowley was appointed Chief Financial Officer of Merus in November 2016. He has over 20 years of global financial and operational experience in the life sciences industry. Most recently, he served as Corporate Senior Vice President, Corporate Controller and Chief Accounting Officer of Charles River Laboratories, Inc. Previously, he was the Vice President, […]